Conformia Integrates SOA-Based Product/Process Lifecycle Management Into IBM Platform for Pharmaceutical Development

IBM Platform Now Includes SOA-Validated Development and Scale Up Management System Software for a More Robust End-to-End Solution

SUNNYVALE, CA–(EMWNews – August 18, 2008) – Conformia, the market leader and innovator of

enterprise solutions for product/process lifecycle management (PPLM) for

regulated process manufacturing industries, today announced it has

integrated its solution into the IBM platform to provide an end-to-end

solution for drug development to the pharmaceutical industry. The solution

incorporates service oriented architecture (SOA) capabilities that have

been validated by IBM. Conformia’s SOA approach enables other applications

running on the IBM stack and infrastructure to exchange crucial

pharmaceutical data with Conformia’s products. Furthermore, data from

non-IBM products can now be integrated into Conformia and IBM product

stacks creating the first commercial off-the-shelf, integrated information

environment solution for pharmaceutical and biotech drug development.

Conformia fulfilled the IBM PartnerWorld® SOA validation criteria for

their solution in December, and is working with IBM to deliver both the

strategic business transformation and the commercial off-the-shelf software

systems that pharmaceutical developers need to support sustainability of

their transformation strategies. With the Conformia SOA platform, drug

developers will be able to reduce development lifecycles, increase

operational visibility and traceability, improve product quality, and

decrease the costs associated with regulatory non-compliance — all while

achieving major gains in data integration.

Working together, Conformia and IBM provide the pharmaceutical industry

with enterprise software on a reliable, robust technology stack that links

data around early experiments, pilot plant scale-up as well as full-scale

manufacturing, along with proven business processes and deployment

capabilities.

“As one of the most heavily regulated and complex industries, the

pharmaceutical sector presents a myriad of unique challenges to

organizations during their product-development lifecycles, and, until now,

few have stepped forward to help,” said Dan Pelino, general manager, IBM

Global Healthcare and Life Sciences. “Together, Conformia and IBM are

helping to deliver a clear path for these organizations to follow — one

that allows them to create an integrated data and information environment

resulting in more effective knowledge-management programs, which they are

now demanding.”

“Combining our deep pharmaceutical and biotech expertise with IBM’s

strength in pharmaceutical industry business transformation delivers a

groundbreaking new approach to help companies implement new development

strategies such as the Quality by Design Paradigm or the ICH Quality

Vision. This helps solve some of the biggest issues in drug development,”

said Anjali Kataria, founder and chief marketing officer of Conformia. “Our

work with IBM both validates and strengthens our continued dedication to

making product development more efficient so scientific leadership can do

more with the same resources.”

About Conformia

Conformia Software is the leading provider of product/process lifecycle

management (PPLM) software solutions to regulated process industries

including life sciences. Conformia solutions enable faster time to market,

reduced costs and decreased risk. As a company, Conformia remains a thought

leader in addressing the most pressing issues facing pharmaceutical

development teams across the globe such as implementation of ICH Quality

Vision. For more information, go to: www.conformia.com.